CORe presented the below oral presentations at ECTRIMS 2024

Sharmin et al

Long-term disability outcomes among children with multiple sclerosis treated with high-efficacy therapy

Müller et al

Guiding Treatment De-escalation in Relapsing Remitting Multiple Sclerosis

Supplementary short report

CORe presented the below posters at ECTRIMS 2024

Dzau et al

The effect of natalizumab and interferon beta on disability in secondary progressive multiple sclerosis: analysis of two phase 3 randomised trials

Giofre et al

The topography of infratentorial lesions in depression and anxiety associated with multiple sclerosis

Kalincik et al

Effectiveness of autologous haematopoietic stem cell transplantation in comparison with immune-reconstitution therapies in relapse-remitting MS

Lizak et al

Managing disease activity during treatment with natalizumab in relapse-remitting multiple sclerosis

Muller et al

A standardised definition of progression independent of relapse activity in multiple sclerosis

Roos et al

Preserving neurological function in patients at high and low risk of aggressive multiple sclerosis

Roberts et al

Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 years

Sharmin et al

How patients with neuromyelitis optica spectrum disorder accumulate disability

Susin et al

Polyhedral predictive model for multiple sclerosis: an external validation

 

 

 

CORe presented the below posters at ECTRIMS 2023

Poster 1 – Roos et al

Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapse-remitting MS

Poster 2 – Moradi et al

The prognostic role of Vitamin D in predicting treatment response in MS

Poster 3 – Moradi et al

The prognostic role of volumetric MRI for predicting treatment response in MS

 

We presented the below posters at the ECTRIMS Conference 2022.

Poster 1 – Kalincik et al

Comparative effectiveness of autologous haematopoieticstem cell transplantation with immune reconstitution therapies in RRMS

Poster 2 – Sharmin et al

The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

Poster 3 – Moradi et al

Does serum neurofilament light chain level contribute to the prediction of treatment response in multiple sclerosis?

 

 

MS Australia

We presented the below posters at the MS Australia
Progress in MS Research Scientific Conference 2022.

Poster 1 – Roos et al

Disease reactivation after cessation of disease-modifying therapy in relapsing-remitting multiple sclerosis

Poster 2 – Roos et al

Effects of high- and low- efficacy therapy in secondary progressive multiple sclerosis

Poster 3 – Roberts et al

Lessons learned in the first two years of a specialist multiple sclerosis cognitive clinic

Poster 4 – Diouf et al

Comparisons of multiple disease modifying therapies in multiple sclerosis with marginal structural models

Poster 5 – Diouf et al

Variability of the response to immunotherapy among sub-groups of patients with multiple sclerosis

Poster 6 – Moradi et al

MS Cohorts and Treatment Utilization in the Middle East

Poster 7 – Sharmin et al

Confirmed disability progression as a marker of permanent disability in multiple sclerosis

 

ECTRIMS 2021

We presented the below posters at ECTRIMS Congress 2021.